Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07160205Phase 2Recruiting

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Role: lead

NCT07086521Phase 1Recruiting

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

Role: lead

NCT04723303Early Phase 1Completed

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

Role: collaborator

NCT04494386Phase 1Completed

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

Role: lead

All 4 trials loaded